Over
the past few years, oligonucleotide developers have outsourced complex
manufacturing procedures to specialty contract manufacturing service providers,
in order to address growing demand competitively, economically and profitably
Roots
Analysis
has announced the addition of “Oligonucleotide Synthesis, Modification
and Purification Services Market: Focus on Research, Diagnostic and Therapeutic
Applications, 2021-2030” report to its list of offerings.
Since
the approval of the first antisense drug in 1998, oligonucleotides have paved
their way into the therapeutic segment, owing to their ability to treat a
myriad of disease indications and high target specificity. This presents
lucrative opportunities for contract service providers that offer manufacturing
services for this rapidly evolving class of pharmacological intervention. As a
consequence, oligonucleotide manufacturers are increasingly strengthening their
capabilities and capacities, in order to cater to the growing demand.
To
order this 360+ page report, which features 175+ figures and 225 + tables, please visit https://www.rootsanalysis.com/reports/304/request-sample.html
Key
Market Insights
Over
95 companies claim to offer oligonucleotide manufacturing services
The
Oligonucleotide
Synthesis market landscape is currently dominated by the
presence of small firms (1-50 employees), which represents close to 41% of the
total number of industry stakeholders. This is followed by mid-sized players
(~30%), and large and more established firms (~29%). Further, close to 14% of
the service providers claim to offer manufacturing services for research
diagnostic and therapeutic applications.
Partnership
activity has increased at a CAGR of over 47% within this domain, since 2014
Majority
of the agreements (34%) were inked to offer manufacturing services to
oligonucleotide-based product developers, followed by instances of mergers /
acquisitions (26%), aimed at the consolidation of existing service portfolios.
Multiple
expansion initiatives were undertaken by service providers, between 2015 and
2021
Over
49% of such initiatives were focused on establishment of new facilities,
followed by expansion of manufacturing-related capabilities (26%). Further, the
US emerged as the most active country (in terms of number of expansion
initiatives), followed by China and Germany.
440+
oligonucleotides focused clinical trials have been registered, worldwide
The clinical research activity (in
terms of number of trials registered) increased at a CAGR of 41%, during the
period 2013-2020. Of the total number of trials, close to 67% have already been
completed, while 31% studies are presently active.
North
America has emerged as oligonucleotide manufacturing hub, in terms of installed
capacity
At
present, the annual, installed manufacturing capacity in US and EU is estimated
to capture around 80% of the available global capacity. This is primarily
driven by players having commercial scale expertise / capabilities.
Demand
for oligonucleotides is anticipated to grow at a CAGR of 10.5%, during
2021-2031
Given
the fact that several oligonucleotide-based drug products were approved in the
last 3-4 years, the commercial demand for oligonucleotides is anticipated to
increase in the near future. Interestingly, over 76% of the estimated
commercial demand was observed to have generated from antisense
oligonucleotides.
Antisense
Oligonucleotides and siRNAs are anticipated to capture over 86% of the market
share in 2030
At
present, the aforementioned types of oligonucleotides capture close to 79% of
the total revenues. It is worth mentioning that the contract manufacturing
market for oligonucleotides in Asia-Pacific is anticipated to grow at a
relatively faster pace (20%).
Key geographical regions
(North America, Europe, and Asia-Pacific and rest of the world)
In order to account for the uncertainties
associated with the Oligonucleotide Synthesis Market Growth and to add robustness
to our model, we have provided three forecast scenarios, portraying the
conservative, base and optimistic tracks of the market’s evolution.
To
request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/reports/304/request-sample.html
Key
Questions Answered
§ Who
are the leading players offering oligonucleotide synthesis, modification and purification
services for research, diagnostic and therapeutic applications?
§ What
are the preferred modification and purification methods used for
oligonucleotides?
§ What
are the key challenges faced by stakeholders engaged in this domain?
§ What
kind of partnership models are commonly adopted by industry stakeholders?
§ What
are the recent expansion initiatives undertaken by service providers within
this domain?
§ Which
therapy developers are likely to partner with oligonucleotide manufacturing
service providers?
§ What
is the annual, clinical and commercial demand for oligonucleotides?
§ What
is the current, installed manufacturing capacity for oligonucleotides?
§ What
percentage of oligonucleotide manufacturing operations are outsourced to
service providers?
§ What
factors should be taken into consideration while deciding whether the
manufacturing operations for oligonucleotides should be kept in-house or
outsourced?
§ What
are the different initiatives undertaken by big pharma players engaged in this
domain, in the recent past?
§ What
are the opportunities in emerging markets for oligonucleotide manufacturing?
§ How
is the current and future market opportunity likely to be distributed across
key market segments?
§ What
are the anticipated future trends related to oligonucleotide manufacturing?
The
financial opportunity within the oligonucleotide synthesis, modification and
purification market has been analyzed across the following segments:
§ Application
Area
§ Research
and Diagnostic Applications
§ Therapeutic
Applications
§ Type
of Oligonucleotide
§ Antisense
Oligonucleotides
§ miRNA
§ shRNA
§ siRNA
§ Others
§ Scale
of Operation
§ Clinical
§ Commercial
§ Purpose
of Production
§ In-house
Operations
§ Outsourced
Operations
§ Type
of Operation
§ API
§ FDF
§ Size
of Manufacturer
§ Small
§ Mid-sized
§ Large
§ Key
Therapeutic Areas
§ Autoimmune
Disorders
§ Cardiovascular
Disorders
§ Genetic
Disorders
§ Infectious
Diseases
§ Metabolic
Disorders
§ Neuromuscular
Disorders
§ Oncological
Disorders
§ Ophthalmic
Disorders
§ Other
Therapeutic Areas
§ Key
Geographical Regions
§ North
America
§ Europe
§ Asia-Pacific
and the Rest of the World
The
report features inputs from eminent industry stakeholders, according to whom,
the oligonucleotide manufacturing services market is primarily driven by the
increasing demand for such molecules, for use in diagnostic and therapeutic
applications. The report includes detailed transcripts of discussions held with
the following experts:
§
Arun Shastry (Co-Founder and Managing
Director, Hanugen Therapeutics)
§
Hans-Peter Vornlocher (Managing Director, Axolabs)
§
Joachim Bertram (Chief Scientific Officer
and Managing Director, IBA
Life Sciences)
§
Tobias Pohlmann (Founder and Managing
Director, BianoScience)
The re
Facebook Conversations